Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Editorial Board236
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer224
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer221
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty162
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in139
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review138
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives130
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group117
Systemic therapy for older patients with early breast cancer107
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis97
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas90
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer84
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)80
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials79
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications78
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma78
De-escalation strategies with targeted therapies in non-small cell lung cancer72
Editorial Board72
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches71
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.68
If it’s a target, it’s a pan-cancer target: Tissue is not the issue64
Emerging antibody-based therapies for the treatment of acute myeloid leukemia64
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features63
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis63
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?62
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis61
Optimizing care in early phase cancer trials: The role of palliative care60
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era58
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment56
Editorial Board55
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck52
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC52
Uncertainties and controversies in axillary management of patients with breast cancer52
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?51
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations49
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes46
Roadmap to cure multiple myeloma46
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment46
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy45
Editorial Board44
Extracellular vesicles and the “six Rs” in radiotherapy43
Overview of BH3 mimetics in ovarian cancer43
Editorial Board42
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review42
The immunogram of inflammatory breast cancer41
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis41
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design41
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis41
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier41
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma40
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]40
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities38
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features37
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside37
Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis37
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma37
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives37
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada36
Long-term surveillance recommendations for young adult cancer survivors36
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review35
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)35
De-escalation of axillary irradiation for early breast cancer – Has the time come?35
Agnostic drug development revisited34
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer34
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies34
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers34
Editorial Board34
Immunocytokines in cancer treatment: A systematic review33
Bone complications of cancer treatment32
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies31
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer31
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review30
Editorial Board30
Malignant ascites: Current therapy options and treatment prospects30
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life30
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers29
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?29
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?29
Editorial Board29
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review29
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications28
Acknowledgement to Reviewers 202128
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review28
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification28
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review27
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes27
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review27
Local control strategies for management of NSCLC with oligoprogressive disease27
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges26
Genomic distinctions in adolescent and young adult cancer: A comprehensive review26
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review26
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project25
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis24
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer24
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence24
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis24
Pharmacotherapy for leptomeningeal disease in breast cancer23
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives23
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie23
Engineering strategies to optimise adoptive cell therapy in ovarian cancer23
Evolving immunotherapeutic solutions for triple-negative breast carcinoma23
Strategies for improving detection of circulating tumor DNA using next generation sequencing23
Review: Targeting EZH2 in neuroblastoma23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]23
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis22
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression22
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications22
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond22
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review22
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies22
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors22
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review21
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases21
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives21
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies21
SELNET clinical practice guidelines for soft tissue sarcoma and GIST21
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment20
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis20
Editorial Board20
Editorial Board20
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature20
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis20
0.89198398590088